HMGA2 induces epithelial-to-mesenchymal transition in human hepatocellular carcinoma cells

YIZHOU LUO1*, WENFENG LI2* and HUI LIAO1

1Department of Oncology and Hematology, Jun Xie Hospital, Nanjing, Jiangsu 210002; 2Department of Radiation Oncology, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang 325000, P.R. China

Received November 7, 2012; Accepted February 5, 2013

DOI: 10.3892/ol.2013.1193

Abstract. Epithelial-to-mesenchymal transition (EMT) is an important event during tumorigenesis. The human high-mobility group A2 (HMGA2) is a chromatin-binding protein, which contains three AT-hook domains that enable its binding to the minor groove of DNA. HMGA2 organizes protein complexes on enhancers of various genes to regulate gene expression and cell differentiation. The HMGA2 protein has been reported to be overexpressed in many types of cancer. It is not known, however, whether HMGA2 regulates EMT in human hepatocellular carcinoma (HCC) cell lines, and the mechanism(s) have not been fully elucidated. In this study, the expression of HMGA2 in five HCC cell lines was examined. The levels of HMGA2 expression among the five HCC cell lines coincided with their invasiveness. The variation in HMGA2 expression significantly correlated with the expression of several putative EMT markers. In addition, assessment of the invasive potential, following transfection with HMGA2-siRNA, demonstrated that the rate of cell migration was significantly reduced, suggesting that HMGA2 may be an important contributor to the invasion of tumor cells and that expression levels of HMGA2 influence the metastatic behavior of HCC cells. To further confirm the conclusion and explore the molecular mechanism through which HMGA2 induces EMT, we found that HMGA2 upregulates the expression of Twist and Snail in HCC cell lines. In conclusion, this present study is the first to show that HMGA2 effectively regulates EMT to induce invasion and metastasis in HCC cells. The function of HMGA2 as an oncoprotein may be associated with several important molecules involved in invasion and metastasis of cancer cells.

Introduction

Epithelial-to-mesenchymal transition (EMT) is an important event during tumorigenesis (1). The functional loss of E-cadherin protein, a key protein maintaining epithelial cell-cell adhesion, is a key marker in the EMT process (2). Several transcriptional repressors, such as the zinc finger factors Snail, Slug, ZEB1 and ZEB2, the basic helix-loop-helix (bHLH) factor E47 and Twist have been identified as strong repressors of E-cadherin expression and have been implicated in tumor progression (2).

Human high-mobility group A2 (HMGA2) is a chromatin-binding protein which contains three AT-hook domains that enable its binding to the minor groove of DNA. HMGA2 organizes protein complexes on enhancers of various genes to regulate gene expression and cell differentiation (3,4). HMGA2 protein is overexpressed in many types of cancer, such as lung cancer (5), ovarian cancer (6), breast cancer (7), oral squamous cell carcinoma (8), pancreatic cancer (9) and colorectal cancer (10). Previous studies have demonstrated how HMGA2 promotes cancerogenesis at the molecular level. For example, it is well-known that human telomerase reverse transcriptase (hTERT) is essential for tumor cell proliferation and self-renewal. HMGA2 increases hTERT transcription to promote tumorigenesis (11). Certain micro RNAs (miRNAs) are able to target HMGA2 gene, which inhibits tumorigenesis through the downregulation of HMGA2 protein (12). The role of HMGA2 that controls EMT has been well-described. Transforming growth factor-b (TGF-β) induces the expression of HMGA2 by activating transcription factor Smad. HMGA2 associates with Smad complexes to induce Snail and Twist expression, two established regulators of EMT, which finally leads to mesenchymal transition (13,14).

It is not known whether HMGA2 regulates EMT in human hepatocellular carcinoma (HCC) cell lines; furthermore, the mechanism(s) have not been fully elucidated.

Material and methods

Cell culture. PLC/PRF/5, Huh-7, HepG2, and Hep3B cells (nonmetastatic or low metastatic potential human HCC cell lines) used in this study were obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA) and
MHCC97-H cells human HCC cell lines with high metastatic potential were established at the Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China (15). All cells were cultured in the corresponding medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin and were maintained in a 37°C incubator with 5% CO₂.

The study was approved by the Ethics Committee of Jun Xie Hospital, Nanjing, China.

Transfection. HepG2 cells were transiently transfected with HA-tagged human HMGA2 using FuGENE HD (Roche Applied Science, Mannheim, Germany). Transient transfections of MHCC97-H cells with siRNA against human Hmga2 (ON-TARGETplus SMARTpool L-013495; Dharmacon, Pittsburgh, PA, USA) or non-targeting siRNA control were done using DharmaFECT1 siRNA transfection reagent (Dharmacon). The effectiveness of gene overexpression or silencing was determined using real-time PCR and western blot analysis.

Real-time PCR. Total-RNA was extracted using the RNeasy mini kit (Qiagen, Valencia, CA, USA) and the concentration detected using a biological spectrophotometer. Real-time PCR analysis was performed according to the manufacturer’s instructions (Quant SYBR-Green PCR kit, Tiangen Biotech, Beijing, China). Primers for mouse glyceraldehyde-3-phosphate dehydrogenase (Gapdh) were used as a reference. The primers for Gapdh were 5'-TGTGTCCGTCGTGGATC (sense) and 5'-TCCCTCTAAAGCAGCTCAAAA3' (antisense). The primers for Hmga2 were 5'-TCCCTCTAAAGCAGCTCAAAA3' (sense) and 5'-ACTTGGTGTGCGCATTTTCTT3' (antisense). Gene expression levels were determined with the comparative Ct method using Gapdh as a reference. The control condition was set to 1 or 100% and expression levels are presented as bar graphs of means ± standard error of the mean (SEM).

Western blot analysis. A total of 1x10⁵ cells were collected. The cells were lysed and the protein concentrations were measured using a BCA Protein Assay Reagent kit (Pierce, Rockford, USA). A 20 μg aliquot of the protein was subjected to 10% SDS-polyacrylamide gel electrophoresis (PAGE), and transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA, USA). After being blocked by incubation overnight in PBST containing 5% dry nonfat milk, the PVDF membrane was incubated with the indicated primary antibodies (1:1,000 dilution) for 2 h and incubated with a horseradish-peroxidase-conjugated secondary antibody (1:100 dilution; Proteintech, Chicago, IL, USA) for 1 h. Immunoreactive bands were visualized using an enhanced chemiluminescence (ECL) detection system (Amersham, Arlington Heights, IL, USA). β-actin was detected simultaneously as a loading control (anti-β-actin, 1:1,000 dilution; Kangchen, Beijing, China).

Invasion and migration assay. For the invasion assay, cell culture inserts (8 μm, 24-well format, Becton-Dickinson Labware, Franklin Lakes, NJ, USA) were evenly coated with diluted Matrigel (1:5 dilution with blank medium). Cells (1x10⁵) were added to the upper chamber and the lower chamber was filled with 300 μl medium containing 10% FBS. The culture was maintained for 24 h. The cell migration assay was similar to the invasion assay, except that inserts were not coated with Matrigel and the culture was maintained for 24 h. Cells were fixed with 4% formaldehyde for 10 min and stained with 0.5% crystal violet for 10 min. The cells on the upper side of the filters were removed with cotton-tipped swabs. The cells on the underside of the filters were counted under a x20 objective lens in five randomly selected fields. The results are presented as the fold change when compared with vector control cells.

Statistical analysis. All experiments were performed in triplicate. Results are expressed the mean ± SEM. A two-tailed Student's t-test was performed to analyze the statistical significance of differences between experimental groups using the SPSS 11.5 software statistical package (SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant result.

Results

Expression of HMGA2 in five HCC cell lines at the mRNA and protein level. To establish the correlation between HMGA2 expression and HCC cell lines, five HCC cell lines were evaluated for HMGA2 mRNA expression using quantitative PCR (qPCR) and expression at protein level using western blot analysis. HMGA2 was highly expressed in MHCC97-H cells that were characterized as high metastatic potential (Fig. 1A and B). In contrast, the nonmetastatic or low metastatic potential cells almost completely lacked HMGA2 or showed decreased expression (Fig. 1A and B).

Overexpression of HMGA2 promotes, but silencing inhibits EMT. To verify whether HMGA2 regulates EMT in HCC cell lines, HA-HMGA2 was transiently transfected into low metastatic HepG2 cells or the expression of HMGA2 was knocked down using siRNA in MHCC97-H cells. HMGA2 overexpression induced downregulation of the epithelial marker E-cadherin expression at the protein and mRNA levels; furthermore, mesenchymal genes such as vimentin or N-cadherin expression at the protein and mRNA levels were induced by HMGA2 overexpression (Fig. 2A).

![Figure 1. The expression of human high-mobility group A2 (HMGA2) in five hepatocellular carcinoma (HCC) cell lines at the mRNA and protein level.](image-url)
HMGA2 knockdown also affects EMT marker variation was examined. HMGA2 knockdown could increase E-cadherin expression and decrease vimentin or N-cadherin expression at both the protein and mRNA levels (Fig. 2B).

Ectopic expression of HMGA2 promotes, but depletion blocks tumor cell migration and invasion. The regulatory effect of HMGA2 on migratory and invasive ability was examined using transwell migration and invasion assays. HMGA2 overexpression promotes the migration and invasion of HepG2 cells (Fig. 3A and B), whereas knockdown of HMGA2 blocked the migration and invasion of MHCC97-H cells (Fig. 3C and D). These data suggest that HMGA2 participates in the regulation of HCC cell migration and invasion.

**Discussion**

*Hmga2* is a member of the HMGA family that encodes a chromatin-associated protein (3). In humans, the *Hmga2* gene is located at chromosome 12q14 and encodes a 109 amino acid protein. In embryonic tissues, HMGA2 is essential for normal cardiac development (16) and increases the frequency and self-renewal of fetal and young-adult stem cells (17), thereby regulating cell growth and differentiation. Moreover, the role of HMGA2 that participates in the process of tumorigenesis has been studied extensively. The functional significance of HMGA2 in HCC cell lines, however, is still not clear. Elucidating its functional roles and molecular mechanisms involved in the tumorigenesis may, therefore, be helpful for the early diagnosis and development of malignancies.

In this study, the expression of HMGA2 in five HCC cell lines was examined at the mRNA level using real-time PCR and at the protein level by western blot analysis. The level of HMGA2 expression among the five HCC cell lines coincided with their invasiveness, which was consistent with a previous
observation that increased expression of HMGA2 correlated with increased invasiveness in tumor tissues (18). Many successive steps are required for a growing benign hyperplasia to evolve into a fully malignant and metastatic cancer (1). EMT is a critical event that enables cancer cells to invade the local tissue, acquire competence for intravasation and generate progeny with tumor-initiating capacities (2). During EMT, differentiated epithelial cells lose their cell-cell adhesions, become more motile and exhibit mesenchymal features. For example, loss of E-cadherin expression, a key molecule of the adherens junction and a tumor suppressor gene (CDH1) and induction of vimentin-based intermediate filaments are two of the many established hallmarks of the EMT process (3). To demonstrate the role of HMGA2 in EMT, the expression of HMGA2 was silenced using siRNA in MHCC97-L cells with highly invasive potential and high HMGA2 expression. Concurrently, we overexpressed HMGA2 in HepG2 cells with low invasion and HMGA2 low expression. The variation of HMGA2 expression was found to correlate significantly with the expression of several putative EMT markers. In addition, assessment of the invasive potential following transfection with HMGA2-siRNA demonstrated that the rate of cell migration was significantly reduced compared with that in siControl and mock control samples, suggesting that HMGA2 may be an important contributor to the invasion of tumor cells, and that the expression level of HMGA2 influences the metastatic behavior of HCC cells.

The large number of cellular events that characterize the mesenchymal transition are thought to be collectively regulated by a group of transcription factors that coordinate the transcriptional program of EMT. These transcriptional regulators are the zinc finger factors Snail, Snail2 (also known as Slug), ZEB1, ZEB2 and the basic helix-loop-helix factors E47 and Twist1 (Twist) (4). Previously, Moustakas and his group demonstrated that HMGA2 binds directly to the Twist or Snail promoter to induce EMT using HepG2 cells. To further confirm the conclusion and explore the molecular mechanism by which HMGA2 induces EMT, it was assumed that HMGA2 upregulates the expression of Twist and Snail in HCC cell lines. Indeed, HMGA2 was found to increase the expression of the two proteins at both the mRNA and protein level. Since it was also demonstrated that HMGA2 regulates the TGF-β signaling pathway, future research should be carried out to elucidate whether HMGA2 has correlations with TGF-β in EMT in HCC cell lines.

In conclusion, the present study is the first to show that HMGA2 effectively regulates EMT to prompt invasion and metastasis in HCC cells. The function of HMGA2 as an oncoprotein may be associated with several important molecules involved in invasion and metastasis of cancer cells. These results further indicate that HMGA2 may serve as a potential target for the development of therapies for HCC, although additional detailed studies in vivo are required.

Acknowledgements

This study was supported in part by grants from the Nanjing military medical scientific research projects (10MA053) and Zhejiang Provincial Natural Science Foundation of China (LY12H31003).

References

1. Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science 331: 1559-1564, 2011.
2. Qin Q, Xu Y, He T, Qin C, Xu J: Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res 22: 90-106, 2012.
3. Fusco A and Fedele M: Roles of HMGA proteins in cancer. Nat Rev Cancer 7:899-910, 2007.
4. Sgarra R, Zammiti S, Lo Sardo A, et al: HMGA molecular network: from transcriptional regulation to chromatin remodeling. Biochim. Biophys. Acta 1799: 37-47, 2010.
5. Sarhadi VK, Wikman H, Salmenkivi K, et al: Increased expression of high mobility group A proteins in lung cancer. J Pathol 209: 206-212, 2006.
6. Shell S, Park SM, Radjabi AR, et al: Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 104: 11400-11405, 2007.
7. Langelotz C, Schmid P, Jakob C, et al: Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br J Cancer 88: 1406-1410, 2003.
8. Miyazawa J, Mitoro A, Kawashiri S, Chada KK and Imai K: Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 64: 2024-2029, 2004.
9. Dangi-Garimella S, Krantz SB, Barron MK, et al: Threedimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res 71: 1019-1028, 2011.
10. Wang X, Liu X, Li AY, et al: Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clin Cancer Res 17: 2570-2580, 2011.
11. Li AY, Lin HH, Kuo CY, et al: High-mobility group A2 protein modulates htERT transcription to promote tumorigenesis. Mol Cell Biol 31: 2605-17, 2011.
12. Palmieri D, D’Angelo D, Valentino T, et al: Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene 31: 3857-3865, 2012.
13. Tan EJ, Thuault S, Caja L, Carletti T, Heldin CH and Moustakas A: Regulation of transcription factor Twist expression by the DNA architectural protein high mobility group A2 during epithelial-to-mesenchymal transition. J Biol Chem 287: 7134-7145, 2012.
14. Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH and Moustakas A: HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem 283: 33437-33446, 2008.
15. Li Y, Yang ZY, Ye SL, et al: Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97-L. World J Gastroenterol 7: 630-636, 2001.
16. Monzen K, Ito Y, Naito AT, et al: A crucial role of a high mobility group protein HMGA2 in cardiogenesis. Nat Cell Biol 10: 567-574, 2008.
17. Nishino J, Kim J, Chada K and Morrison SF: HMga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf expression. Cell 135: 227-239, 2008.
18. Fabjani G, Tong D, Wolf A, et al: HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. Oncol Rep 14: 737-741, 2005.